Insulin Resistance May Contribute to Worse Prognosis in Black Women with Breast Cancer

Article

Insulin resistance was found to be 1 factor that contributes to the worse prognosis in breast cancer between black and white women, potentially through direct effects of insulin on the tumor insulin receptor.

A study of US women with newly diagnosed invasive breast cancer published in Breast Cancer Research found that insulin resistance is 1 factor that contributes to the worse prognosis in breast cancer between black and white women, potentially through direct effects of insulin on the tumor insulin receptor (IR).1

Given the differences in circulating insulin levels and tumor IR expression between black and white women, the researchers indicated that it will be important in future studies to explore whether lowering insulin levels or targeting IR signaling will improve breast cancer survival disparities. 

“Given that obesity and diabetes epidemics disproportionately affect minority populations, it is important to understand the relationship of hyperinsulinemia, insulin resistance, and increased insulin receptor (IR) signaling on the progression of breast cancer,” lead author Emily J. Gallagher, MD, PhD, assistant Professor of Medicine at the Icahn School of Medicine at Mount Sinai, said in a press release.2 “Understanding these relationships could explain the different patterns of disease seen in different racial groups and help to identify patients who would benefit from targeted therapy.”

The cross-sectional, multi-center study was conducted across 10 hospitals and recruited self-identified black women and white women with newly diagnosed invasive breast cancer. The primary outcome was to determine if insulin resistance, which was calculated using the homeostatic model assessment of insulin resistance (HOMA-IR), mediated the effect of race on prognosis using the multivariate linear mediation model.

Of the 515 women recruited, 83% were white women and 17% were black women. Overall, the metabolic syndrome of insulin resistance was found to be more prevalent in black women than in white women (40% vs 20%; P < 0.0001). Moreover, HOMA-IR was higher in black women than in white women (1.9 ± 1.2 vs 1.3 ± 1.4; P = 0.0005). 

Poor breast cancer prognosis was also found to be more prevalent in black women than in white women (28% vs 15%; P = 0.004). Even further, HOMA-IR was positively associated with NPI score (r = 0.1; P = 0.02). 

The mediation model, adjusted for age, demonstrated that HOMA-IR significantly mediated the correlation between black race and poor prognosis (β = 0.04, 95% CI 0.005-0.009, P = 0.002). In addition, IR expression was higher in tumors from black women than in those from white women (79% vs 52%, p = 0.004), and greater IR/insulin growth factor 1 receptor [IGF-1R] ratio was also associated with higher NPI score (IR/IGF-1R > 1: 4.2 ± 0.8 vs IR/IGF-1R = 1: 3.9 ± 0.8 vs IR/IGF-1R < 1: 3.5 ± 1.0; P < 0.0001).

“Our results raise a number of questions for future research and patient care. It will be important in future studies to explore whether lowering insulin levels or targeting IR signaling will improve breast cancer disparities,” co-senior investigator Nina Bickell, MD, PhD, MPH, associate director of Community Engaged and Equity Research of The Tisch Cancer Institute and co-director of the Center for Health Equity and Community Engaged Research at the Icahn School of Medicine at Mount Sinai, said in a press release.

Notably, the researchers had incomplete data on some breast cancer risk factors, including reproductive history and parity. Additionally the prevalence of obesity as defined by BMI was lower in this study than expected for a US population. The researchers indicated that this likely to explain the lower than anticipated HOMA-IR results. 

“While the focus of our study was to examine the link between insulin resistance and disparities in prognosis in women with newly diagnosed breast cancer, we acknowledge that this is certainly just one of a number of complex factors that contribute to racial disparities in breast cancer prognosis,” the authors wrote.

References:

1. Gallagher EJ, Fei K, Feldman SM, et al. Insulin resistance contributes to racial disparities in breast cancer prognosis in US women. Breast Cancer Research. doi:10.1186/s13058-020-01281-y

2. Insurance Resistance Contributes to Racial Disparities in Breast Cancer Prognosis in U.S. Women, Mount Sinai Researchers Reveal [news release]. New York, NY. Published May 12, 2020. newswise.com/articles/insulin-resistance-contributes-to-racial-disparities-in-breast-cancer-prognosis-in-u-s-women-mount-sinai-researchers-reveal?sc=dwhr&xy=10019792. Accessed May 12, 2020. 

Recent Videos
Heather Zinkin, MD, states that reflexology improved pain from chemotherapy-induced neuropathy in patients undergoing radiotherapy for breast cancer.
Study findings reveal that patients with breast cancer reported overall improvement in their experience when receiving reflexology plus radiotherapy.
Patients undergoing radiotherapy for breast cancer were offered 15-minute nurse-led reflexology sessions to increase energy and reduce stress and pain.
Whole or accelerated partial breast ultra-hypofractionated radiation in older patients with early breast cancer may reduce recurrence with low toxicity.
Ultra-hypofractionated radiation in those 65 years or older with early breast cancer yielded no ipsilateral recurrence after a 10-month follow-up.
The unclear role of hypofractionated radiation in older patients with early breast cancer in prior trials incentivized research for this group.
Patients with HR-positive, HER2-positive breast cancer and high-risk features may derive benefit from ovarian function suppression plus endocrine therapy.
Paolo Tarantino, MD discusses updated breast cancer trial findings presented at ESMO 2024 supporting the use of agents such as T-DXd and ribociclib.
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.
Related Content